US8036071004
US8036071004
Sarepta Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 65/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±70.4% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).
Beta (Market Relation)
0.38x
DefensiveVolatility (5Y p.a.)
70.4% p.a.
5-Year HorizonMax Drawdown (5Y)
-92.7%
5-Year HorizonSharpe Ratio
-0.44
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -22.1% |
| 3 Years | 80.9% | -92.7% | -0.61 | -47.2% |
| 5 Years | 70.4% | -92.7% | -0.44 | -28.8% |
| 10 Years | 65.7% | -93.3% | -0.2 | -10.9% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Elevated Short-Term Volatility: 3Y volatility (80.9%) is noticeably higher than the 5Y average (70.4%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (70.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -93.3% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
6 ISS Score: 6 / 10
Audit Risk
7 ISS Score: 7 / 10
Board Risk
2 ISS Score: 2 / 10
Short Ratio
8.24